vs
STANDARD BIOTOOLS INC.（LAB）与NORTHERN TECHNOLOGIES INTERNATIONAL CORP（NTIC）财务数据对比。点击上方公司名可切换其他公司
NORTHERN TECHNOLOGIES INTERNATIONAL CORP的季度营收约是STANDARD BIOTOOLS INC.的1.2倍（$23.3M vs $19.6M），NORTHERN TECHNOLOGIES INTERNATIONAL CORP净利率更高（1.0% vs -177.4%，领先178.4%），NORTHERN TECHNOLOGIES INTERNATIONAL CORP同比增速更快（9.2% vs -11.5%），NORTHERN TECHNOLOGIES INTERNATIONAL CORP自由现金流更多（$-479.7K vs $-23.1M），过去两年NORTHERN TECHNOLOGIES INTERNATIONAL CORP的营收复合增速更高（5.8% vs -12.2%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
该企业为一家美国航天科技公司，专注于地理空间情报、地球观测、在轨卫星服务业务，同时提供卫星产品及相关配套服务。其由数字地球公司与MDA控股公司合并而成，于2017年10月5日正式完成合并组建。
LAB vs NTIC — 直观对比
损益表 — Q3 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $19.6M | $23.3M |
| 净利润 | $-34.7M | $237.8K |
| 毛利率 | 48.5% | 36.0% |
| 营业利润率 | -168.5% | 4.0% |
| 净利率 | -177.4% | 1.0% |
| 营收同比 | -11.5% | 9.2% |
| 净利润同比 | -28.8% | -57.6% |
| 每股收益（稀释后） | $-0.09 | $0.03 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | — | $23.3M | ||
| Q3 25 | $19.6M | $22.3M | ||
| Q2 25 | $21.8M | $21.5M | ||
| Q1 25 | $40.8M | $19.1M | ||
| Q4 24 | — | $21.3M | ||
| Q3 24 | $22.1M | $23.3M | ||
| Q2 24 | $22.5M | $20.7M | ||
| Q1 24 | $45.5M | $20.8M |
| Q4 25 | — | $237.8K | ||
| Q3 25 | $-34.7M | $-1.1M | ||
| Q2 25 | $-33.5M | $121.8K | ||
| Q1 25 | $-26.0M | $434.3K | ||
| Q4 24 | — | $561.1K | ||
| Q3 24 | $-26.9M | $1.8M | ||
| Q2 24 | $-45.7M | $976.6K | ||
| Q1 24 | $-32.2M | $1.7M |
| Q4 25 | — | 36.0% | ||
| Q3 25 | 48.5% | 37.9% | ||
| Q2 25 | 48.8% | 38.4% | ||
| Q1 25 | 48.4% | 35.6% | ||
| Q4 24 | — | 38.3% | ||
| Q3 24 | 54.9% | 43.8% | ||
| Q2 24 | 46.1% | 38.2% | ||
| Q1 24 | 53.1% | 40.0% |
| Q4 25 | — | 4.0% | ||
| Q3 25 | -168.5% | 4.2% | ||
| Q2 25 | -118.1% | 4.0% | ||
| Q1 25 | -80.8% | -1.7% | ||
| Q4 24 | — | 5.2% | ||
| Q3 24 | -120.9% | 11.8% | ||
| Q2 24 | -134.5% | 7.4% | ||
| Q1 24 | -132.2% | 10.6% |
| Q4 25 | — | 1.0% | ||
| Q3 25 | -177.4% | -4.9% | ||
| Q2 25 | -153.7% | 0.6% | ||
| Q1 25 | -63.8% | 2.3% | ||
| Q4 24 | — | 2.6% | ||
| Q3 24 | -122.0% | 7.9% | ||
| Q2 24 | -203.3% | 4.7% | ||
| Q1 24 | -70.6% | 8.2% |
| Q4 25 | — | $0.03 | ||
| Q3 25 | $-0.09 | $-0.11 | ||
| Q2 25 | $-0.09 | $0.01 | ||
| Q1 25 | $-0.07 | $0.04 | ||
| Q4 24 | — | $0.06 | ||
| Q3 24 | $-0.07 | $0.19 | ||
| Q2 24 | $-0.12 | $0.10 | ||
| Q1 24 | $-0.27 | $0.17 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | $6.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $399.7M | $72.4M |
| 总资产 | $539.6M | $104.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | — | $6.4M | ||
| Q3 25 | $129.4M | $7.3M | ||
| Q2 25 | $158.6M | $6.8M | ||
| Q1 25 | $150.9M | $5.1M | ||
| Q4 24 | — | $5.6M | ||
| Q3 24 | $210.6M | $5.0M | ||
| Q2 24 | $269.8M | $5.8M | ||
| Q1 24 | $287.1M | $4.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $55.2M | — | ||
| Q2 24 | $55.1M | — | ||
| Q1 24 | $55.0M | — |
| Q4 25 | — | $72.4M | ||
| Q3 25 | $399.7M | $72.1M | ||
| Q2 25 | $424.5M | $72.4M | ||
| Q1 25 | $454.6M | $69.7M | ||
| Q4 24 | — | $70.2M | ||
| Q3 24 | $489.3M | $71.2M | ||
| Q2 24 | $510.3M | $68.9M | ||
| Q1 24 | $577.3M | $68.4M |
| Q4 25 | — | $104.0M | ||
| Q3 25 | $539.6M | $102.7M | ||
| Q2 25 | $557.0M | $99.3M | ||
| Q1 25 | $579.6M | $93.7M | ||
| Q4 24 | — | $94.0M | ||
| Q3 24 | $681.5M | $94.7M | ||
| Q2 24 | $708.7M | $89.3M | ||
| Q1 24 | $777.7M | $87.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.11× | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | 0.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $341.9K |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | $-479.7K |
| 自由现金流率自由现金流/营收 | -118.1% | -2.1% |
| 资本支出强度资本支出/营收 | 4.5% | 3.5% |
| 现金转化率经营现金流/净利润 | — | 1.44× |
| 过去12个月自由现金流最近4个季度 | $-111.1M | $-1.8M |
8季度趋势，按日历期对齐
| Q4 25 | — | $341.9K | ||
| Q3 25 | $-22.2M | $-1.4M | ||
| Q2 25 | $-20.7M | $609.7K | ||
| Q1 25 | $-30.3M | $803.7K | ||
| Q4 24 | — | $2.4M | ||
| Q3 24 | $-27.9M | — | ||
| Q2 24 | $-39.0M | $1.9M | ||
| Q1 24 | $-62.5M | — |
| Q4 25 | — | $-479.7K | ||
| Q3 25 | $-23.1M | $-1.4M | ||
| Q2 25 | $-22.6M | $-171.2K | ||
| Q1 25 | $-35.3M | $293.1K | ||
| Q4 24 | — | $1.2M | ||
| Q3 24 | $-30.1M | — | ||
| Q2 24 | $-41.0M | $869.4K | ||
| Q1 24 | $-63.3M | — |
| Q4 25 | — | -2.1% | ||
| Q3 25 | -118.1% | -6.3% | ||
| Q2 25 | -103.6% | -0.8% | ||
| Q1 25 | -86.6% | 1.5% | ||
| Q4 24 | — | 5.5% | ||
| Q3 24 | -136.4% | — | ||
| Q2 24 | -182.2% | 4.2% | ||
| Q1 24 | -138.9% | — |
| Q4 25 | — | 3.5% | ||
| Q3 25 | 4.5% | 0.2% | ||
| Q2 25 | 8.7% | 3.6% | ||
| Q1 25 | 12.4% | 2.7% | ||
| Q4 24 | — | 5.7% | ||
| Q3 24 | 10.2% | — | ||
| Q2 24 | 8.6% | 5.2% | ||
| Q1 24 | 1.7% | — |
| Q4 25 | — | 1.44× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 5.01× | ||
| Q1 25 | — | 1.85× | ||
| Q4 24 | — | 4.27× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 1.99× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
NTIC
| Inside The USA To Unaffiliated Customers | $7.5M | 32% |
| Natur Tec | $6.0M | 26% |
| Acobal | $3.6M | 15% |
| Other | $2.7M | 12% |
| BR | $2.1M | 9% |
| Zerust OY | $1.4M | 6% |
